Program Description
Obesity is a complex, chronic disease that is associated with numerous comorbidities, including diabetes, hypertension, and cardiovascular disease. Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA therapies are used in the management of obesity and associated cardiometabolic risk. These therapies promote weight loss through multiple mechanisms, including regulation of gastrointestinal hormones and delayed gastric emptying, resulting in reduced appetite and caloric intake. However, delayed gastric emptying can lead to gastrointestinal adverse effects and decreased caloric intake can lead to deficiencies in essential nutrients. Patients receiving GLP-1 RA and GIP/GLP-1 RA therapies may require individualized nutritional counseling and support to ensure long-term treatment persistence. This panel discussion reviews the identification, counseling, and monitoring of patients receiving GLP-1 RA and GIP/GLP-1 RA therapies, with an emphasis on the pharmacist’s role in nutritional assessment and management. The discussion features an expert interview with a nutritionist who provides an interdisciplinary perspective on integrating nutritional support into pharmacist-led care for patients receiving GLP-1 RA and GIP/GLP-1 RA therapies.
Target audience: Community Pharmacists
Type of activity: Application
Release date: December 15, 2026
Expiration date: February 15, 2027
Time to complete activity: 1.5 hours
Learner level: Intermediate
Fee: Free
Educational Objectives
After completion of this activity, participants will be able to:
- Identify appropriate patient candidates for glucagon-like peptide-1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA therapy, including risk factors for nonadherence and treatment discontinuation
- Explain key screening and counseling considerations to optimize the use of GLP-1 RAs and dual GIP/GLP-1 RA therapy throughout treatment
- Explore interprofessional interventions to support adherence to GLP-1 RAs and dual GIP/GLP-1 RA therapy, including motivational interviewing, nutrition expertise, and care coordination
Accreditation Information
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This application-based activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-26-320-L01-P. The activity is available for CE credit through February 15, 2027.
Obtaining Credit
All participants who attended the live virtual broadcast need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Instructions on receiving credit will be provided the day of the event.
Disclosures
Sneha Srivastava, PharmD, BCACP, CDCES, DipACLM, FADCES, has the following relevant financial relationship with an ineligible company to disclose:
Speakers Bureau: Xeris Pharmaceuticals
Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES, FADCES, FCCP, has the following relevant financial relationship with an ineligible company to disclose:
Consultant: MiniMed, Tandem
Speakers Bureau: Abbott, CeQur, Dexcom, Insulet, Lilly, Novo Nordisk, Sanofi, Sequel Pharma
Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, has the following relevant financial relationships with ineligible companies to disclose:
Speakers Bureau: Abbott Diabetes, Amgen, CeQur, Lilly, Novo Nordisk, Xeris
Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Brynn Gilbert, PharmD; Sarah Viruet; and Brianna Winters have no financial relationships with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
At least 1
anonymous peer reviewer has been used as part of content validation and
conflict resolution. The peer reviewer has no relevant financial relationships
with ineligible companies to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not
constitute any form of professional advice or referral. Discussions concerning
drugs, dosages, and procedures may reflect the clinical experience of the
author(s) or they may be derived from the professional literature or other
sources and may suggest uses that are investigational in nature and not
approved labeling or indications. Participants are encouraged to refer to primary
references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms